Not Yet Recruiting
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent - CA239-0028
Aggiornato:
20 luglio, 2026
|
ClinicalTrials.gov.
Stampi il riassunto semplice
Dettagli della sperimentazione
-
Phase 1
Fase
-
Sesso
-
18-60
Fascia d'età
-
1
Sede/i
-
Not Yet Recruiting
Opzioni di trattamento
Principali criteri di idoneità
Inclusion Criteria: - Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese). - Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator. - Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2. - Participants must have Total body weight ≥ 50 kg. Exclusion Criteria: - Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator. - Other protocol defined Inclusion/Exclusion criteria apply.